[1] 王宁,刘硕,杨雷,等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志,2019, 5(01): 87-97. [2] Karaayyaz M, Cristea S, Gillespie SM, et al.Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq[J]. Nat Commun, 2018, 9(1): 3588. [3] Lee KL, Kuo YC, Ho YS, et al.Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness[J]. Cancers (Basel), 2019,11(9): 1334. [4] Bareche Y, Venet D, Ignatiadis M, et al.Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis[J]. Ann Oncol, 2018, 29(4): 895-902. [5] Burstein MD, Tsimelzon A, Poage GM, et al.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer[J]. Clin Cancer Res, 2015, 21(7): 1688-1698. [6] Santucci-Pereira J, Zeleniuch-Jacquotte A, Afanasyeva Y, et al.Genomic signature of parity in the breast of premenopausal women[J]. Breast Cancer Res, 2019, 21(1): 46. [7] Kumar S, Wilkes DW, Samuel N, et al.Delta Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer[J]. J Clin Invest, 2018, 128(11): 5095-5109. [8] Zeng Y, Wang CL, Xian J, et al.Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer[J]. Onco Targets Ther, 2019,12: 7193-7201. [9] Yu S, Cai X, Wu C, et al.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer[J]. Int J Biol Sci, 2017, 13(4): 505-517. [10] He Y, Jiang Z, Chen C, et al.Classification of triple-negative breast cancers based on Immunogenomic profiling[J]. J Exp Clin Cancer Res, 2018, 37(1): 327. [11] Zhang QQ, Chen J, Zhou DL, et al.Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer[J]. Int J Biol Sci, 2017,13(4): 471-479. [12] Qian X, Song X, He Y, et al.CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients[J]. Biomed Pharmacother, 2015, 74: 222-227. [13] Shekhar R, Priyanka P, Kumar P, et al.The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression[J]. J Biol Chem, 2019, 294(12): 4381-4400. [14] Xie B, Wang S, Jiang N, et al.Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance[J]. Cancer Lett, 2019, 443: 56-66. [15] Liu G, Zhao J, Pan B, et al.UBE2C overexpression in melanoma and its essential role in G2/M transition[J]. J Cancer, 2019,10(10): 2176-2184. [16] Gluz O, Kolberg-Olberg-Liedtke C, Prat A, et al. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial[J]. Int J Cancer, 2020, 146(1): 262-271. [17] Zheng H, Li X, Chen C, et al.Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer[J]. Int J Nanomedicine, 2016, 11: 5519-5529. [18] Fu X, Chen G, Cai ZD, et al.Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer[J]. Onco Targets Ther, 2016, 9: 2211-2220. [19] Ma Q, Liu Y, Shang L, et al.The FOXM1/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma[J]. Oncol Rep, 2017, 38(6): 3367-3375. [20] Meng QC, Wang HC, Song ZL, et al.Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and regulates cell proliferation[J]. Am J Cancer Res, 2015, 5(5): 1730-1740. [21] Bai J, Li Y, Zhang G.Cell cycle regulation and anticancer drug discovery[J]. Cancer Biol Med, 2017, 14(4): 348-362. [22] von Wahlde MK, Hülsewig C, Ruckert C, et al. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling[J]. Gynecol Endocrinol, 2015, 31(2): 160-164. [23] Apaya MK, Hsiao PW, Yang YC, et al.Deregulating the CYP2C19/Epoxy-Eicosatrienoic Acid-Associated FABP4/FABP5 Signaling Network as a Therapeutic Approach for Metastatic Triple-Negative Breast Cancer[J]. Cancers (Basel), 2020, 12(1): 199. [24] Xiao Y, Li Y, Tao H, et al.Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway[J]. Cancer Lett, 2018, 433: 199-209. [25] Scintu M, Vitale R, Prencipe M, et al.Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma[J]. Cancer Lett, 2007, 254(2): 298-307. [26] Dang SC, Qian XB, Jin W, et al.G-protein-signaling modulator 2 expression and role in a CD133+pancreatic cancer stem cell subset[J]. Onco Targets Ther, 2019, 12: 785-794. [27] Zhang L, Li J, Lv X, et al.MID1-PP2A complex functions as new insights in human lung adenocarcinoma[J]. J Cancer Res Clin Oncol, 2018, 144(5): 855-864. [28] Mo D, Li C, Liang J, et al.Low PBRM1 identifies tumor progression and poor prognosis in breast cancer[J]. Int J Clin Exp Pathol, 2015, 8(8): 9307-9313. [29] Long R, Liu Z, Li J, et al.COL6A6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway[J]. Aging (Albany NY), 2019, 11(20): 8845-8859. [30] Ackermann A, Schrecker C, Bon D, et al.Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer[J]. PLoS One, 2019, 14(3): e0213411. [31] Li N, Xue W, Yuan H, et al.AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis[J].J Clin Invest, 2017, 127(4): 1284-1302. [32] Yeom CJ, Zeng L, Goto Y, et al.LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis[J]. Oncotarget, 2016, 7(40): 65837-65848. [33] Yu SY, Wang YP, Chang JY, et al.Increased expression of MCM5 is significantly associated with aggressive progression and poor prognosis of oral squamous cell carcinoma[J]. J Oral Pathol Med, 2014, 43(5): 344-349. [34] Zhou C, Sun J, Zheng Z, et al.High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection[J].Ann Transl Med, 2020, 8(7): 466. |